COG 133 is primarily researched for its potential therapeutic applications in the field of neurodegenerative diseases, particularly Alzheimer's disease. It is a peptide that interacts with amyloid-beta, a protein fragment implicated in the formation of plaques in the brains of Alzheimer's patients. By binding to amyloid-beta, COG 133 may help prevent the aggregation of these plaques, which are thought to contribute to neuronal damage and cognitive decline. This mechanism makes it a promising candidate for developing treatments aimed at slowing or halting the progression of Alzheimer's disease. Additionally, its neuroprotective properties are being explored for potential use in other conditions involving amyloid-related pathology. Research is ongoing to further understand its efficacy and safety in clinical settings.